Research programme: neuropilin-1 receptor antagonists - Ark Therapeutics

Drug Profile

Research programme: neuropilin-1 receptor antagonists - Ark Therapeutics

Alternative Names: EG0048; EG012; EG012-014; EG01257; EG014; EG3287

Latest Information Update: 23 Nov 2012

Price : $50

At a glance

  • Originator Ark Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Neuropilin-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 08 Nov 2012 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
  • 22 May 2012 Preclinical development is ongoing in United Kingdom
  • 11 Mar 2011 The neuropilin-1 receptor antagonists programme is available for licensing \www.arktherapeutics.com\
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top